Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles ESC Heart Failure Year : 2021

Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry

1 UWr - University of Wrocław [Poland]
2 University hospital of Zurich [Zurich]
3 KU Leuven - Catholic University of Leuven - Katholieke Universiteit Leuven
4 Fondazione Policlinico Universitario Agostino Gemelli IRCCS
5 IRCCS - Istituto di Ricovero e Cura a Carattere Scientifico
6 HUG - Geneva University Hospital
7 Herlev and Gentofte Hospital
8 UCPH - University of Copenhagen = Københavns Universitet
9 CHUAC - Complejo Hospitalario Universitario A Coruña [A Coruña, Spain]
10 INIBIC - Instituto de Investigación Biomédica de A Coruña [La Corogne, Espagne]
11 CIBERCV - Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares [Spain]
12 Cliniques universitaires St Luc [Bruxelles]
13 IREC - Institut de Recherche Expérimentale et Clinique
14 Università degli studi di Trieste = University of Trieste
15 Medical University of Graz
16 Temple University [Philadelphia]
17 CBmed GmbH - Center for Biomarker Research in Medicine [Graz, Austria]
18 MSH - Mustafakemalpasa State Hospital [Bursa, Turkey]
19 Centro Cardiologico Monzino [Milano]
20 UNIMI - Università degli Studi di Milano = University of Milan
21 APL - Johns Hopkins University Applied Physics Laboratory [Laurel, MD]
22 LUKS - Luzerner Kantonsspital [Lucerne, Switzerland]
23 UNT - University Nicolae Testemitanu [Kishinev, Moldova]
24 CIC - Poitiers
25 Hospital "Magalini" Villafranca - ULSS 9 Scaligera [Verona, Italy]
26 PHCVO - Public Health Company Valle Olona [Busto Arsizio, Italy]
27 ZOL - Ziekenhuis Oost-Limburg
28 UHasselt - Hasselt University
29 CHU Reims - Centre Hospitalier Universitaire de Reims
30 Mersin University
31 CarMeN - Cardiovasculaire, métabolisme, diabétologie et nutrition
32 Hôpital Louis Pradel [CHU - HCL]
33 CIC1407 - Centre d'Investigation Clinique [Bron]
34 UFPE - Universidade Federal de Pernambuco [Recife]
35 Juntendo University Hospital [Tokyo]
36 IC2D - Institute for Cardiovascular Diseases Dedinje [Belgrade, Serbia]
37 University of Belgrade [Belgrade]
38 Medical University of Warsaw - Poland
39 University Hospital of Ioannina
40 University of Medicine Greifswald
41 DZHK - German Center for Cardiovascular Research
42 ZNA Heart Centre [Antwerp, Belgium]
43 GHIB - German Heart Institute Berlin [Berlin, Germany]
44 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
45 Deutsches Herzzentrum Berlin
46 Karolinska Institute
47 Karolinska University Hospital [Stockholm]
48 IRCCS San Raffaele [Rome, Italy]
49 Wrocław Medical University
C. Bouleti
  • Function : Author
A. Celik
  • Function : Author


AIMS: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations. METHODS AND RESULTS: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62-81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44-2.59], P \textless 0.001). After adjusting, HF remained associated with in-hospital mortality (OR 1.45 [95% confidence interval: 1.01-2.06], P = 0.041). Importantly, 186 of 1282 [15%] patients had an acute HF event during hospitalization (76 [40%] with de novo HF), which was associated with higher in-hospital mortality (89 [48%] vs. 220 [23%]) than in patients without HF event (OR 3.10 [2.24-4.29], P \textless 0.001). CONCLUSIONS: Hospitalized COVID-19 patients with HF are at increased risk for in-hospital death. In-hospital worsening of HF or acute HF de novo are common and associated with a further increase in in-hospital mortality.
Fichier principal
Vignette du fichier
ESC Heart Failure - 2021 - Sokolski - Heart failure in COVID‐19 the multicentre multinational PCHF‐COVICAV registry.pdf (2.39 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03582037 , version 1 (21-02-2022)



M. Sokolski, S. Trenson, J. M. Sokolska, D. d'Amario, P. Meyer, et al.. Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry. ESC Heart Failure, 2021, 8 (6), pp.4955-4967. ⟨10.1002/ehf2.13549⟩. ⟨inserm-03582037⟩
23 View
15 Download



Gmail Facebook Twitter LinkedIn More